Regenerative medicine and bioengineered tissues by Humacyte
Symvess acellular vessel introduced at live simulation event by Humacyte
Humacyte is hosting a Hands-On Simulation Lab featuring its Symvess acellular tissue engineered vessel-type (ATEV) technology today and tomorrow. The VAM TOUCHPOINT Hands-On / SIM Lab allows ...
Humacyte announces interim results from women-only vascular access study
Humacyte is set to present interim results from its women-only study on arteriovenous (AV) access. The forum will address clear unmet needs in AV access for women, a segment often underrepresented ...
U.S. Veterans Affairs to expand access to Humacyte Symvess implant under new agreement
Humacyte has announced it has secured a contract with the Strategic Acquisition Center of the U.S. Department of Veterans Affairs to provide its Symvess acellular tissue engineered vessel. This ...
Humacyte presents new data on acellular tissue engineered vessels for dialysis access at VASA
Humacyte is set to present new scientific research on acellular tissue engineered vessels at the Vascular Access Society of the Americas (VASA) meeting. The study examines the performance of ...
Humacyte estimates delayed emergency care in vascular trauma puts life and limb at elevated risk
Vascular injuries can result in severe consequences, including limb loss and life-threatening complications. Humacyte reports that 20 percent of patients arrive at the hospital more than five ...
Humacyte Marketing Authorization for Symvess acellular vessel accepted by Israel Ministry of Health
The Israel Ministry of Health has accepted Humacyte Marketing Authorization Application for its Symvess acellular, tissue engineered vessel intended for urgent arterial injury repair. A review ...
Symvess off the shelf vessel approved for rapid vascular injury response, Humacyte unveils
Humacyte has introduced Symvess, a ready-to-use, human-derived, bioengineered vessel designed for the treatment of extremity vascular injuries. Symvess is described as the first and only FDA ...
Humacyte invites vascular experts to spring events to explore Symvess and ATEV products
Humacyte is engaging with the vascular medical community this spring by participating in several regional and national meetings. The company will showcase its portfolio, including the Symvess ...
Innovation focus at Humacyte aims to advance healthier future for patients
Humacyte marks World Health Day with renewed commitment to medical innovation and patient care. The company reiterated its mission to leverage science, compassion, and collaboration as core ...
Humacyte secures minimum 1.475 million dollar Symvess vessel purchase for Saudi clinical rollout
Humacyte has received a minimum 1.475 million dollar purchase commitment for its Symvess acellular tissue–engineered vessel, to be deployed in a clinical evaluation and outreach program in the ...
Humacyte seeks Israeli approval for Symvess acellular vessel as breakthrough repair option
Humacyte has submitted a Marketing Authorization Application to the Israel Ministry of Health for Symvess, its acellular, tissue-engineered vessel designed for urgent arterial injury repair. This ...
Humacyte promotes critical role of vascular health in February
February marks American Heart Month, a time dedicated to acknowledging the significance of vascular health in life-saving efforts. Humacyte, a leader in bioengineering, aims to improve patient ...
Humacyte set to unveil advances in vascular surgery innovation
Humacyte is gearing up to present significant advancements in its acellular tissue-engineered vessel, Symvess™, at various events this February and March. The company will focus on promoting ...
Humacyte releases press info on VEITH symposium presentation
Humacyte has released a press statement detailing their presentations scheduled at the VEITH symposium. The company highlights today's sessions, including the Podium Session 8 on Concourse A at ...
Humacyte signals comprehensive education on Acellular Tissue Engineered Vessel at VEITH Symposium
Humacyte is gearing up for a significant presence at the VEITH Symposium 2025. The company will offer six presentations focusing on its Acellular Tissue Engineered Vessel, providing substantial ...
Humacyte introduces Symvess at Veith Symposium
Humacyte, a leading innovator in bioengineered vessels, is showcasing its latest technology, Symvess, at the Veith Symposium in New York. The company is offering hands-on demonstrations at Booth ...
